VG Life Sciences announced an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors. The study reported two clinical responses in cohort 3 with disease stabilization in a patient with metastatic ovarian cancer for 4 months, and disease stabilization going into its fifth month in a patient with triple negative breast cancer. The final patient in cohort #3 has stage IV (metastatic) adenocarcinoma of the lung.

The four separate lung lesions have all regressed about 20%. The study, which is ongoing in patients with refractory or relapsed solid tumors, examines the safety and efficacy of hydroxychloroquine (HCQ), in combination with sorafenib (marketed as Nexavar(R)), which was co-developed by Bayer AG and Onyx Pharmaceuticals.